Compare TUSK & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TUSK | PYXS |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 141.3M |
| IPO Year | 2016 | 2021 |
| Metric | TUSK | PYXS |
|---|---|---|
| Price | $3.39 | $3.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 168.9K | ★ 939.3K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.32 | 3.03 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $44,292,000.00 | $13,858,000.00 |
| Revenue This Year | $383.90 | N/A |
| Revenue Next Year | N/A | $7,043.98 |
| P/E Ratio | $26.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.72 | $0.97 |
| 52 Week High | $3.92 | $5.55 |
| Indicator | TUSK | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 72.22 |
| Support Level | $2.54 | $3.67 |
| Resistance Level | $3.54 | $4.58 |
| Average True Range (ATR) | 0.14 | 0.29 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 94.90 | 99.67 |
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.